Antibodies have long been recognised as potent vectors for carrying diagnostic medical radionuclides, contrast agents and optical probes to diseased tissue for imaging. The area of ImmunoPET combines the use of positron emission tomography (PET) imaging with antibodies to improve the diagnosis, staging and monitoring of diseases. Recent developments in antibody engineering and PET radiochemistry have led to a new wave of experimental ImmunoPET imaging agents that are based on a range of antibody fragments and affibodies. In contrast to full antibodies, engineered affibody proteins and antibody fragments such as minibodies, diabodies, single‐chain variable region fragments (scFvs), and nanobodies are much smaller but retain the essential spe...
The high specificity and affinity of antibodies make them attractive for developing drugs to diagnos...
The noninvasive detection and quantification of CD8+ T cells in vivo are important for both the dete...
Drug development, including agents targeting the immune system, have improved patient survival in mu...
The use of fluorine-18 as a radionuclide for positron emission tomography (PET) has become increasin...
Exploiting antibodies' highly specific binding affinities to various biomarkers, immuno-positron emi...
With the landscape-transforming arrival of cancer immunotherapy, such as drugs that block immune che...
During the past decade, the efficacy of new molecular targeted drugs such as monoclonal antibodies h...
Antibodies are currently the fastest-growing class of therapeutics. Although naked antibodies have p...
Presently, hundreds of monoclonal antibodies (mAbs) and mAb fragments are under clinical development...
Cancer immunotherapy allows a relevant new treatment strategy for patients with cancer. Especially i...
Abstract. Molecular imaging techniques for protein therapeutics rely on reporter labels, especially ...
Item does not contain fulltextDue to their high target affinity and specificity, antibodies are very...
Despite promise for the use of antibodies as molecular imaging agents in PET, their long in vivo hal...
Despite promise for the use of antibodies as molecular imaging agents in PET, their long in vivo hal...
Prolonged clearance kinetics have hampered the development of intact antibodies as imaging agents, d...
The high specificity and affinity of antibodies make them attractive for developing drugs to diagnos...
The noninvasive detection and quantification of CD8+ T cells in vivo are important for both the dete...
Drug development, including agents targeting the immune system, have improved patient survival in mu...
The use of fluorine-18 as a radionuclide for positron emission tomography (PET) has become increasin...
Exploiting antibodies' highly specific binding affinities to various biomarkers, immuno-positron emi...
With the landscape-transforming arrival of cancer immunotherapy, such as drugs that block immune che...
During the past decade, the efficacy of new molecular targeted drugs such as monoclonal antibodies h...
Antibodies are currently the fastest-growing class of therapeutics. Although naked antibodies have p...
Presently, hundreds of monoclonal antibodies (mAbs) and mAb fragments are under clinical development...
Cancer immunotherapy allows a relevant new treatment strategy for patients with cancer. Especially i...
Abstract. Molecular imaging techniques for protein therapeutics rely on reporter labels, especially ...
Item does not contain fulltextDue to their high target affinity and specificity, antibodies are very...
Despite promise for the use of antibodies as molecular imaging agents in PET, their long in vivo hal...
Despite promise for the use of antibodies as molecular imaging agents in PET, their long in vivo hal...
Prolonged clearance kinetics have hampered the development of intact antibodies as imaging agents, d...
The high specificity and affinity of antibodies make them attractive for developing drugs to diagnos...
The noninvasive detection and quantification of CD8+ T cells in vivo are important for both the dete...
Drug development, including agents targeting the immune system, have improved patient survival in mu...